Do HSV-1, HSV-2, and varicella-zoster virus stay latent in sensory ganglia and reactivate later?

After primary HSV-1, HSV-2, or varicella-zoster virus (VZV) infection, lifelong sensory-neuronal latency with potential later reactivation is an established feature of these alphaherpesviruses. This is particularly clinically relevant at age 71, when VZV-specific cellular immunity may decline and shingles risk rises.

Clinical evidence

• HSV-1 usually persists in trigeminal ganglia and HSV-2 in lumbosacral dorsal-root ganglia; both can reactivate intermittently, causing recurrent mucocutaneous disease or asymptomatic shedding.
• After varicella, VZV remains latent in trigeminal and dorsal-root sensory ganglia and can reactivate as herpes zoster.
• Impaired cell-mediated immunity materially increases zoster risk. In a meta-analysis of 88 studies encompassing >3.7 million zoster cases, risk was increased with HIV/AIDS (relative risk [RR] 3.22, 95% CI 2.40–4.33) and malignancy (RR 2.17, 95% CI 1.86–2.53). Chemotherapy, transplantation, corticosteroids, biologics, and targeted therapies can further increase risk and severity.

Mechanistic basis

• During latency, viral genomes reside predominantly in sensory-neuron nuclei, generally as nonintegrated episomal DNA. Productive virus is usually undetectable.
• HSV latency includes restricted expression such as latency-associated transcripts; VZV likewise shows restricted rather than fully productive transcription. Local tissue-resident and ganglionic virus-specific T cells are central to suppressing reactivation and replication.

Clinical interpretation

• “Lifelong” describes the accepted biological course, not continuously observed persistence of an identical genome in an individual over decades.
• The immune-reactivation link is strongest and most quantitatively established for VZV. HSV recurrences also worsen with immunosuppression, although blood HSV-specific T-cell measures do not reliably reflect local ganglionic control.

Bottom line

• The claim is well supported: HSV-1, HSV-2, and VZV persist lifelong in sensory ganglia after primary infection and can periodically reactivate, especially when cellular immune containment is reduced.